LA JOLLA, Calif., Jan. 26 /PRNewswire-FirstCall/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) (www.transdelpharma.com), a specialty pharmaceutical company developing non-invasive, topically administered medications, announced today plans to expand its product development programs to include cosmetic/cosmeceutical products, which will utilize the Company's patented transdermal delivery system technology, TransdelTM. The Company has initiated discussions with potential sales and marketing partners for specific cosmetic/cosmeceutical products.
"We are very excited about entering into this new line of business and the expansion of our product portfolio for the Company," stated Dr. Juliet Singh, President and CEO. "The expansion into the cosmetic/cosmeceutical market may allow the Company to generate revenue during 2009."
The Company's patent for its Transdel(TM) technology specifically lists over 500 different drugs in over 60 therapeutic areas, including both approved and established drugs. Besides its lead drug, Ketotransdel(R) (a topical NSAID currently in a Phase 3 trial for acute pain), the Company is exploring potential co-development opportunities with corporate partners to expand its program into other therapeutic areas. The Transdel(TM) technology may also have an application to deliver drugs not listed in its patent, including novel drugs, and the company is seeking partnerships in this area as well.
About Transdel Pharmaceuticals, Inc.
Transdel Pharmaceuticals, Inc. (OTCBB: TDLP.OB) is a specialty pharmaceutical company developing non-invasive, topically- delivered medications. The Company's innovative patented proprietary Transdel(TM) cream formulation technology is designed to facilitate the effective penetration of drugs through the tough skin barrier to reach the target underlying tissues. In the case of Ketotransdel(R), the Transdel(TM) cream allows the active ingredient ketoprofen to reach the target soft tissue and exert its well-known anti-inflammatory and analgesic effects. The Company is also investigating other drug candidates and treatments for transdermal delivery using the patented Transdel(TM) platform technology for products in pain management, other therapeutic areas and for cosmeceutical products. For more information, please visit http://www.transdelpharma.com.
Safe Harbor Statement
Statements made in this release that are not historical in nature constitute forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "plans" "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. These statements are subject to risks and uncertainties that cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, and technological changes. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-KSB filed with the SEC on March 26, 2008. Such documents may be read free of charge on the SEC's web site at www.sec.gov. All forward-looking statements included in this release are made as of the date of this press release, and the Company assumes no obligation to update any such forward-looking statements.
|SOURCE Transdel Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved